AZN Jan 2026 50.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 10:26AM EDT. Market open.
Loading interactive chart...
- Zacks
AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.
- Yahoo Finance UK
Trending tickers: Gold, Ryanair, Nvidia and AstraZeneca
The latest investor updates on stocks that are trending on Monday.
- Business Wire
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
WILMINGTON, Del., May 19, 2024--The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or smoking status.1 The primary results showed that treatment with AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab) led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placeb
© 2024 Yahoo. All rights reserved.